teaser
Drug firm Novartis says its breast cancer drug Femara® (letrozole) can significantly reduce the likelihood of the disease returning even when treatment starts several years after completing tamoxifen therapy.
The Swiss company cited an analysis of a subset of some 2,400 women, published in the Journal of Clinical Oncology, which shows that treatment with Femara, begun several years after completing the recommended five years of tamoxifen, reduced the risk of breast cancer returning by 63%.
The risk of cancer spreading to other areas of the body was reduced by 61% and the median period before starting Femara was 31 months.
